Impact of omitting post-transplant minidose-methotrexate doses in allogeneic hematopoietic cell transplantation

References

• Forman SJ, Negrin RS, Antin JH, et al. Thomas’ hematopoietic cell transplantation. 5th ed. Chichester: John Wiley; 2015.
   Google Scholar
• Zeiser R, Blazar BR. Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med. 2017;377(22):2167–2179.
   PubMed Web of Science ®Google Scholar
• Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314(12):729–735.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Leisenring W, Deeg HJ, et al. Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Biol Blood Marrow Transplant. 2005;11(10):814–815.
   PubMed Web of Science ®Google Scholar
• Yau JC, Dimopoulos MA, Huan SD, et al. An effective acute graft-vs.-host disease prophylaxis with minidose methotrexate, cyclosporine, and single-dose methylprednisolone. Am J Hematol. 1991;38(4):288–292. Dec;
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Ippoliti C, Khouri I, et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood. 1996;88(11):4383–4389.
   PubMed Web of Science ®Google Scholar
• Kumar S, Wolf RC, Chen MG, et al. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease. Bone Marrow Transplant. 2002;30(3):161–165.
   PubMed Web of Science ®Google Scholar
• Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood. 1992;80(7):1838–1845.
   PubMed Web of Science ®Google Scholar
• Armand P, Kim HT, Logan BR, et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664–3671.
   PubMed Web of Science ®Google Scholar
• Mizumoto C, Kanda J, Ichinohe T, et al. Mycophenolate mofetil combined with tacrolimus and minidose methotrexate after unrelated donor bone marrow transplantation with reduced-intensity conditioning. Int J Hematol. 2009;89(4):538–545.
   PubMed Web of Science ®Google Scholar
• Bolwell B, Sobecks R, Pohlman B, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004;34(7):621–625.
   PubMed Web of Science ®Google Scholar
• Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15(3):367–369.
   PubMed Web of Science ®Google Scholar
• Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog‐containing chemotherapy: harnessing graft‐versus‐leukemia without myeloablative therapy. Blood. 1997;89(12):4531–4536.
   PubMed Web of Science ®Google Scholar
• Jakubowski AA, Small TN, Young JW, et al. T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood. 2007;110(13):4552–4559.
   PubMed Web of Science ®Google Scholar
• Chewning JH, Castro-Malaspina H, Jakubowski A, et al. Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts in the treatment of initial graft failure. Biol Blood Marrow Transplant. 2007;13(11):1313–1323.
   PubMed Web of Science ®Google Scholar
• Kim SY, Kim AR, Yoon SY, et al. Substitution of methotrexate with corticosteroid for acute graft-versus-host disease prevention in transplanted patients who develop methotrexate toxicity. Ann Hematol. 2016;95(3):483–491.
   PubMed Web of Science ®Google Scholar
• Hamilton BK, Rybicki L, Dean R, et al. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation. Am J Hematol. 2015;90(2):144–148.
   PubMed Web of Science ®Google Scholar
• Honda A, Kakihana K, Aoki J, et al. Omission of day-11 MTX, in combination with tacrolimus, is not associated with increased risk of acute graft-versus-host disease after allo-BMT. Bone Marrow Transplant. 2013;48(2):307–309.
   PubMed Web of Science ®Google Scholar
• Atkinson K, Downs K. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA identical sibling bone marrow transplantation. Bone Marrow Transplant. 1995;16(6):755–758.
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Spitzer TR, Cottler-Fox M, et al. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. Bone Marrow Transplant. 1991;7(3):193–198.
   PubMed Web of Science ®Google Scholar
• Bensinger W, Stem Cell Trialists’ Collaborative G. Individual patient data Meta-analysis of allogeneic peripheral blood stem cell transplant vs. bone marrow transplant in the management of hematological malignancies: indirect assessment of the effect of day 11 methotrexate administration. Bone Marrow Transplant. 2006;38(8):539–546.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Reljic T, Kumar A, et al. Omission of day +11 methotrexate dose and allogeneic hematopoietic cell transplantation outcomes: results of a systematic review/Meta-analysis. Bone Marrow Transplant. 2022;57(1):65–71. Epub ahead of print. PMID: 34642451.
   PubMed Web of Science ®Google Scholar
• Perkins J, Field T, Kim J, et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2010;16(7):937–947.
   PubMed Web of Science ®Google Scholar
• Chhabra S, Liu Y, Hemmer MT, et al. Comparative analysis of calcineurin inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of graft-versus-host disease after reduced-intensity conditioning allogeneic transplantation. Biol Blood Marrow Transplant. 2019;25(1):73–85.
   PubMed Web of Science ®Google Scholar
• Hamilton BK, Liu Y, Hemmer MT, et al. Inferior outcomes with cyclosporine and mycophenolate mofetil after myeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(9):1744–1755.
   PubMed Web of Science ®Google Scholar
• Flowers MED, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125(4):606–615.
   PubMed Web of Science ®Google Scholar
• Velickovic VM, McIlwaine E, Zhang R, et al. Adverse events in second- and third-line treatments for acute and chronic graft-versus-host disease: systematic review. Ther Adv Hematol. 2020; 11:1–18.
   Web of Science ®Google Scholar
• Yeshurun M, Rozovski U, Pasvolsky O, et al. Efficacy of folinic acid rescue following MTX GVHD prophylaxis: results of a double-blind, randomized, controlled study. Blood Adv. 2020;4(16):3822–3828.
   PubMed Web of Science ®Google Scholar